Investigational drug · Phase 3
NNZ-2591
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Phelan-McDermid Syndrome.
Phase 3Last checked: Nov 20, 2026Latest source record: Nov 9, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
7
Any phase or sponsor naming "NNZ-2591"
First trial start
2025
Nov 12, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "NNZ-2591", any sponsor or status.
Conditions studied
As listed on its trial records.
- Phelan-McDermid Syndrome
Approved drugs for the same conditions: Rare and genetic disease
Largest trials
Live from ClinicalTrials.gov: studies naming "NNZ-2591" as an intervention, largest first.
- An Open-label Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid SyndromePivotal-lookingRecruiting
Neuren Pharmaceuticals LimitedIndustry
NCT07593391 · 180 participants (planned) · Start Jun 8, 2026 · Primary completion Oct 29, 2028
Drug: NNZ-2591 · For: Phelan-McDermid Syndrome
Sites: Birmingham, Alabama; Glendale, California; San Diego, California · 12 sites in all
- A Study of NNZ-2591 in Pediatric Participants With Phelan-McDermid SyndromePivotal-lookingRecruiting
Neuren Pharmaceuticals LimitedIndustry
NCT07281079 · 160 participants (planned) · Start Nov 12, 2025 · Primary completion Oct 31, 2027
Drug: NNZ-2591; Placebo · For: Phelan-McDermid Syndrome
Sites: Birmingham, Alabama; Glendale, California; Palo Alto, California · 18 sites in all
- To Evaluate the Safety, Tolerability and Pharmacokinetics of Oral NNZ-2591 in Healthy VolunteersCompleted
Neuren Pharmaceuticals LimitedIndustry
NCT04379869 · 28 participants · Start May 29, 2020 · Primary completion Feb 11, 2021
Drug: NNZ-2591; Placebo · For: Healthy Volunteers
Sites: Sydney, Australia; Nedlands, Australia
Neuren Pharmaceuticals LimitedIndustry
NCT05025332 · 28 participants · Start Oct 14, 2022 · Primary completion Feb 27, 2024
Drug: NNZ-2591 · For: Pitt Hopkins Syndrome
Sites: Birmingham, Alabama; San Francisco, California; Aurora, Colorado · 5 sites in all
Neuren Pharmaceuticals LimitedIndustry
NCT05025241 · 18 participants · Start Aug 8, 2022 · Primary completion Nov 1, 2023
Drug: NNZ-2591 · For: Phelan-McDermid Syndrome
Sites: Chicago, Illinois; Boston, Massachusetts; Houston, Texas · 4 sites in all
Neuren Pharmaceuticals LimitedIndustry
NCT05011851 · 17 participants · Start Jul 12, 2022 · Primary completion May 13, 2024
Drug: NNZ-2591 · For: Angelman Syndrome
Sites: Randwick, Australia; South Brisbane, Australia; Heidelberg, Australia
Neuren Pharmaceuticals LimitedIndustry
NCT05879614 · 0 participants · Start Sep 1, 2023 · Primary completion Jun 30, 2025
Drug: NNZ-2591 · For: Prader-Willi Syndrome
Sites: San Diego, California; Atlanta, Georgia; Chevy Chase, Maryland · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Erratum: NNZ-2591 in Children and Adolescents With Phelan-McDermid Syndrome: Single-Group, Open-Label, Phase 2 Trial Results.
Neumeyer AM, Srivastava S, Holder JL, et al. · Neurol Genet 2026
- NNZ-2591 in Children and Adolescents With Phelan-McDermid Syndrome: Single-Group, Open-Label, Phase 2 Trial Results.
Neumeyer AM, Srivastava S, Holder JL, et al. · Neurol Genet 2026
- Insulin-like growth factor-1 and its derivatives: potential pharmaceutical application for treating neurological conditions.
Guan J, Mathai S, Liang HP, et al. · Recent Pat CNS Drug Discov 2013
- NNZ-2591, a novel diketopiperazine, prevented scopolamine-induced acute memory impairment in the adult rat.
Guan J, Zhang R, Dale-Gandar L, et al. · Behav Brain Res 2010
- IGF-1 derived small neuropeptides and analogues: a novel strategy for the development of pharmaceuticals for neurological conditions.
Guan J, Gluckman PD · Br J Pharmacol 2009
- A novel diketopiperazine improves functional recovery given after the onset of 6-OHDA-induced motor deficit in rats.
Krishnamurthi RV, Mathai S, Kim AH, et al. · Br J Pharmacol 2009
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.